Your browser doesn't support javascript.
loading
Metabolomic Profile in HFpEF vs HFrEF Patients.
Hage, Camilla; Löfgren, Lars; Michopoulos, Filippos; Nilsson, Ralph; Davidsson, Pia; Kumar, Chanchal; Ekström, Mattias; Eriksson, Maria J; Lyngå, Patrik; Persson, Bengt; Wallén, Hakan; Gan, Li Ming; Persson, Hans; Linde, Cecilia.
  • Hage C; Karolinska Institutet, Department of Medicine, Cardiology unit, Stockholm, Sweden. Electronic address: camilla.hage@sll.se.
  • Löfgren L; Translational Science and Experimental Medicine; Research and early Development, Cardiovascular, Renal and Metabolism, Biopharmaceutical R&D, AstraZeneca, Gothenburg, Sweden.
  • Michopoulos F; Bioscience, Early Oncology R&D, AstraZenenca, Cambridge, UK.
  • Nilsson R; Translational Science and Experimental Medicine; Research and early Development, Cardiovascular, Renal and Metabolism, Biopharmaceutical R&D, AstraZeneca, Gothenburg, Sweden.
  • Davidsson P; Translational Science and Experimental Medicine; Research and early Development, Cardiovascular, Renal and Metabolism, Biopharmaceutical R&D, AstraZeneca, Gothenburg, Sweden.
  • Kumar C; Translational Science and Experimental Medicine; Research and early Development, Cardiovascular, Renal and Metabolism, Biopharmaceutical R&D, AstraZeneca, Gothenburg, Sweden.
  • Ekström M; Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Division of Cardiovascular Medicine Stockholm, Sweden.
  • Eriksson MJ; Karolinska Institutet, Department of Molecular Medicine and Surgery, Stockholm, Sweden.
  • Lyngå P; Karolinska Institutet, Department of Clinical Science and Education, Sodersjukhuset, Stockholm, Sweden.
  • Persson B; Uppsala University, Department of Cell and Molecular Biology, Science for Life Laboratory, Uppsala, Sweden.
  • Wallén H; Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Division of Cardiovascular Medicine Stockholm, Sweden.
  • Gan LM; Early Clinical Development, Research and early Development, Cardiovascular, Renal and Metabolism, Biopharmaceutical R&D, AstraZeneca, Gothenburg, Sweden.
  • Persson H; Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Division of Cardiovascular Medicine Stockholm, Sweden.
  • Linde C; Karolinska Institutet, Department of Medicine, Cardiology unit, Stockholm, Sweden.
J Card Fail ; 26(12): 1050-1059, 2020 Dec.
Article en En | MEDLINE | ID: mdl-32750486
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fibrilación Atrial / Disfunción Ventricular Izquierda / Insuficiencia Cardíaca Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fibrilación Atrial / Disfunción Ventricular Izquierda / Insuficiencia Cardíaca Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Año: 2020 Tipo del documento: Article